Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)

被引：1

作者：

Chan, Stephen Lam

Kaseb, Ahmed Omar

Shi, Wei

Alexander, Laura

Meng, Xianzhang

Park, Cheolhee

Ryan, Kristin

Vogel, Arndt

机构：

[1] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China

[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[3] Jiangsu Hengrui Pharmaceut, Shanghai, Peoples R China

[4] Elevar Therapeut, Ft Lee, NJ USA

[5] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.3_suppl.456

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：456 / 456

页数：1

共 33 条

[31] Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
Cho, B. C.
Rodriguez-Abreu, D.
Hussein, M.
Cobo, M.
Patel, A.
Secen, N.
Gerstner, G.
Kim, D-W.
Lee, Y-G.
Su, W-C.
Huang, E.
Patil, N.
Huang, M.
Zhang, Z.
Wen, X.
Mendus, D.
Hoang, T.
Meng, R.
Johnson, M. L.
ANNALS OF ONCOLOGY, 2021, 32 : S1428 - S1428
[32] First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
Reck, M.
Ciuleanu, T-E.
Cobo, M.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Cheng, Y.
Paz-Ares, L.
Lu, S.
John, T.
Padilla, B.
Sun, X.
Moisei, A.
Yan, J.
Yuan, Y.
Blum, S. I.
Carbone, D. P.
ANNALS OF ONCOLOGY, 2020, 31 : S1187 - S1188
[33] Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.
Gadgeel, Shirish M.
Dols, Manuel Cobo
Felip, Enriqueta
Soria, Jean-Charles
Lee, Ki Hyeong
Lu, Shun
Georgoulias, Vassilis
Fulop, Andrea
Goker, Erdem
Syrigos, Konstantinos N.
Morabito, Alessandro
Coskun, Hasan Senol
Guclu, Salih Zeki
Li, Wei
Popat, Sanjay
Ardizzoni, Andrea
Lungershausen, Juliane
Wang, Bushi
Chand, Vikram K.
Goss, Glenwood D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 →

Patient-reported outcomes (PROs) &lt;65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)

Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)